Switchpoint Bio
Switchpoint Bio is developing an AI-powered epigenomics platform to monitor biological changes during treatment without repeated tissue biopsies.
Switchpoint Bio has raised €4.7M across 1 funding round from 2 investors, most recently a Pre-Seed round in Nov 2026. Based in Helsinki, Finland; active in Healthtech. Data as of Nov 2026.
Total raised
€4.7M
€4,726,235
Funding rounds
1
Investors
2
distinct backers
Active since
2026-11
latest 2026-11
Funding by year
EUR raised per year · 2026 YTDSwitchpoint Bio — funding by year — interactive chart.
Data table
| Switchpoint Bio — funding by year | |
|---|---|
| 2026 | €4.7M |
Signals
High confidenceRaise-next likelihood8
base rate 24% for Pre-Seed
- ▼ Raised very recently
- ▼ Low backer re-investment
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round- 2026-11-11Pre-Seed€4.7Mother investors,Treehouse Delmar Investments
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-11-11 | Pre-Seed | €4.7M | other investors,Treehouse Delmar Investments | View deal → |
Investors
2other investorsTreehouse Delmar Investments
Related news
Similar companies
same sector, similar size- Avenue Biosciences€7.2MFinland · Healthtech
- Koite Health€4.0MFinland · Healthtech
- Surgify Medical€7.0MFinland · Healthtech
- Linio Biotech€4.2MFinland · Healthtech
- Arivin Therapeutics€3.0MFinland · Healthtech
- NADMED€3.5MFinland · Healthtech
Global coverage: FundingData